- Home
- XFOR vs MTLS Comparison
XFOR vs MTLS Comparison
Compare XFOR & MTLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XFOR | MTLS |
|---|---|---|
| Founded | 2014 | 1990 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 377.3M | 431.6M |
| IPO Year | 2017 | 2014 |
Fundamental Metrics
Financial Performance| Metric | XFOR | MTLS |
|---|---|---|
| Price | $3.58 | $7.76 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 838.2K | 153.0K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,500,000.00 | N/A |
| Revenue This Year | N/A | $6.38 |
| Revenue Next Year | N/A | $6.45 |
| P/E Ratio | ★ N/A | $61.39 |
| Revenue Growth | ★ 150.00 | N/A |
| 52 Week Low | $2.80 | $4.78 |
| 52 Week High | $4.83 | $7.97 |
Technical Indicators
Market Signals| Indicator | XFOR | MTLS |
|---|---|---|
| Relative Strength Index (RSI) | 36.96 | 67.87 |
| Support Level | $3.19 | $6.37 |
| Resistance Level | $3.56 | N/A |
| Average True Range (ATR) | 0.25 | 0.24 |
| MACD | -0.04 | 0.04 |
| Stochastic Oscillator | 32.14 | 80.61 |
Price Performance
Historical ComparisonAbout XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About MTLS Materialise NV
Materialise NV is a provider of 3D-printed medical devices and software and a pioneer in additive manufacturing software and services. The company operates through three principal segments: Materialise Software, Materialise Medical, and Materialise Manufacturing, with the Materialise Medical segment generating maximum revenue. The Materialise Medical segment develops and delivers medical software solutions, medical devices, and related products and services; the Materialise Software segment develops and delivers additive manufacturing software solutions and related services; and the Materialise Manufacturing segment delivers 3D-printed products and related services. The company generates maximum revenue from the United States of America.